Day-1 Innovation Stage
How Day-1 pitch and stage slots are decided
The MedTech Forum 2027 · Innovation Stage · Amplifai selection rubric
Scope: Day-1 Innovation Stage and Startup Zone at The MedTech Forum 2027, Suntec Singapore · dates to be confirmed. Amplifai programmes Day 1 under its agreement with APACMed. Day 2 is not covered by this rubric.
What is on offer
Twelve pitch slots. Three minutes each. Day 1.
That is the whole inventory. Against a roster of more than a hundred listed companies it is a genuinely competitive process, and saying so plainly is better than implying otherwise — an applicant who understands the odds and applies anyway is a better applicant.
The principle
Merit decides who presents. A package decides which slots you may apply for.
Buying a stand, a Day-1 package or a delegate ticket does not add a single point to a score, and no amount of spend substitutes for evidence. Amplifai takes no equity, no success fee, no placement fee and no referral commission in any circumstance, and recommends no supplier.
1Eligibility — pass all five, or the application is not scored
These are gates, not scores. An application failing any one of them is declined with the reason stated, and nothing else about it is assessed.
| Gate | Test |
|---|---|
| E1The entity is real and verifiable | A registry filing — ACRA, ASIC, MCA, Companies House or local equivalent — matching the name applied under. A business unit or division of a larger company may apply, provided the parent is named in the application and named wherever the unit appears. In that case the parent's registration satisfies this gate. |
| E2The premise holds | You still sell the product being pitched. A company that has exited the relevant business is out, however good the product was. |
| E3Governance is clear | No unresolved fraud finding, insolvency proceeding, regulatory enforcement action or auditor resignation touching the applicant. |
| E4Ownership and affiliation are disclosed | You tell us who owns and controls you. Corporate or investor ownership does not disqualify anyone — concealing it does. Where a shareholder is an APACMed member or a distributor to APACMed members, that is disclosed to the room. |
| E5Consent and registration are in place | An Innovator or Solver listing consent is recorded, and the presenting person is registered to attend. |
⚠️ One role per organisation. An organisation participating as a Partner cannot also apply as an innovator.
2Scoring — 100 points across five dimensions
Two reviewers score independently. A slot needs 60 points and no dimension below 40% of its maximum — a strong product with no APAC footing is still the wrong pitch for this room.
2.1 Challenge fit — 20 points
Does the pitch address one of the fifteen challenges, in the framework's own wording?
| Band | Points | Test |
|---|---|---|
| Direct | 16–20 | Addresses a named challenge head-on, and the applicant can say which of the sixty-two filings' language it answers |
| Adjacent | 8–15 | Addresses part of a challenge, or sits between two |
| Loose | 0–7 | The mapping is asserted rather than argued |
2.2 Evidence — 25 points. The heaviest dimension, deliberately.
| Band | Points | Test |
|---|---|---|
| Deployed and measured | 20–25 | A named health system, hospital or manufacturer using it, willing to be named, with a before-and-after number and a stated source |
| Deployed | 12–19 | A named reference site, outcome described but not quantified |
| Piloted | 5–11 | A live pilot, no completed outcome yet |
| Asserted | 0–4 | Claims without a reference |
Clinical evidence, where the product makes a clinical claim, is scored on OCEBM 2011 Levels 1–5 and on nothing else. A systematic review outranks a case series; a case series outranks a testimonial.
2.3 Asia-Pacific relevance — 20 points
| Band | Points | Test |
|---|---|---|
| Operating | 16–20 | Regulatory clearance or an active deployment in at least one of the twelve APAC markets, plus people in the region |
| Entering | 8–15 | A named APAC market entry underway, with a regulatory pathway identified |
| Interested | 0–7 | APAC is a plan |
⚠️ APAC headquarters is not required and earns no points by itself. What counts is whether the room can buy this here.
2.4 Readiness to transact — 15 points
Can a procurement or corporate development team act on this within a year? Assessed on technology readiness, device risk class and regulatory status where applicable, delivery capability against the deployment being claimed, and whether the commercial model is stated plainly.
2.5 What the room learns — 20 points
The dimension most applicants ignore and the one that most often decides a tie.
The Day-1 audience is mixed: multinational strategy and procurement teams, hospital and health-system leaders, government agencies, investors and regulators. A pitch that only makes sense to investors is the wrong pitch.
| Band | Points | Test |
|---|---|---|
| Transferable | 16–20 | Someone who will never buy this product still leaves with something they can use |
| Specific | 8–15 | Useful to a defined slice of the room |
| Promotional | 0–7 | A product demonstration with no general lesson |
3Ties, and what breaks them
In order:
- Higher evidence score (2.2). Evidence beats everything.
- Broader challenge coverage — a challenge with no other representation on the stage is preferred, so the programme covers the framework rather than clustering.
- Asia-Pacific headquarters. Used here and only here.
- Earlier complete application.
⚠️ A package is never a tie-breaker. If two applications are level on all four, both are declined a pitch slot and offered a Startup Zone presence instead, and the slot goes to the next application.
3.1 Twelve slots, fifteen challenges
The two numbers do not divide, and pretending otherwise would make the tie-break rule dishonest. No challenge takes more than one slot until every challenge with a qualifying applicant has had the chance at one. Twelve slots across fifteen challenges means at least three challenges will not be represented on the stage, and the ones that miss out should be the ones with no qualifying applicant — never the ones that simply applied later.
Practical consequence: rank within challenge first, then take the top-ranked applicant from each of the twelve highest-scoring challenges. That is a different result from ranking all applicants globally, and it is the one that makes the stage look like the framework.
4Process
| Apply | One form. No fee. Open to any eligible applicant, whether or not anything has been bought. |
| Screen | Eligibility gates only. Failures are told which gate and why, in one sentence. |
| Score | Two reviewers, independently, without seeing each other's sheet and without seeing what the applicant has bought. |
| Reconcile | Scores more than 15 points apart are discussed and re-scored. A third reviewer breaks a persistent disagreement. |
| Decide | Ranked list. Slots allocated top-down subject to the tie-break rules. |
| Publish | The programme publishes who is presenting. Scores are never published, and no applicant is ever ranked publicly against another. |
| Tell the unsuccessful | Each receives their band per dimension — not their score — and the single thing that would most improve a future application. |
Conflicts of interest. A reviewer with any commercial, advisory, investment or employment relationship with an applicant declares it and recuses from that application. A sponsor may not review. Recusals are logged.
Right of reply. An applicant may correct a factual error in the assessment within three working days. A correction can change a score. A disagreement about judgement cannot.
5Dates
| Applications open | Tuesday, 1 September 2026 |
| Applications close | Saturday, 12 September 2026 |
| Decisions issued | Thursday, 17 September 2026 |
| Slides due | 48 hours before the session |
| Roster and programme freeze | Friday, 25 September 2026 |
| The Forum | Suntec Singapore · dates to be confirmed |
The recommended dates leave eight days between decisions and the freeze, which is the minimum that allows a declined applicant to still take a Startup Zone place and a successful one to prepare properly.
5.1⚠️ Twelve three-minute pitches in a 45-minute window is a production problem, not a rubric problem
Day 1's pitch finals run 14:55–15:40 — 45 minutes. The arithmetic:
| 12 pitches × 3:00 | 36:00 |
| Remaining for everything else | 9:00 |
| Less an opening and a handover, say | 3:00 |
| Left for 11 changeovers | 6:00 — about 33 seconds each |
There is no contingency in that. One overrun cascades into every pitch after it, and the awards moment at 15:40–15:50 has nowhere to absorb it.
- ·One deck, loaded in advance. No laptop swaps, no dongles, no "can you pull up my website". Slides submitted 48 hours ahead or the slot is forfeited.
- ·A visible countdown clock facing the presenter, and a hard stop. The microphone cuts at 3:00 — then it is the rule doing the enforcing, not the MC.
- ·Presenters queued stage-left, next two always standing by.
- ·The MC introduces by name and company only — five seconds. No reading of credentials; the programme carries those.
- ·No Q&A, no judge commentary, no scoring on stage. If any of those are wanted, the number of pitches has to come down.
The honest alternative: ten pitches at the same three minutes gives roughly a minute of slack per changeover and a session that can survive one thing going wrong. Twelve is achievable and it is the right ambition — but it needs the five rules above to be non-negotiable.
6What this rubric deliberately does not do
- ·It does not score how much a company has raised. Funding is not evidence.
- ·It does not score novelty. A boring product that demonstrably works outranks a novel one that does not.
- ·It does not favour APACMed members, and it does not favour non-members.
- ·It does not guarantee anything to anyone, at any spend level.
- ·It does not select solvers for introductions. That is a separate process with separate consent, and a pitch decision has no bearing on it.
Amplifai · operated by NZmark Pte Ltd, Singapore · APACMed's official partner and exclusive operator of the MedTech Forum's Day-1 Innovation Stage and Startup Zone (MTF26–28) · hello@amp-lif-ai.com
Built from the criteria already in use: the nine Solver qualification tests in Amplifai_Canon_Solver_List.xlsx, the taxonomy locked in Amplifai_Innovator_App_BusDev_Spec_v2.2.md (OCEBM 2011 Levels 1–5, TRL, device risk class, twelve APAC markets), the "merit beats package" rule from the same spec, and the Day-1 programme published at medtechforum.asia/program.